METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS

Abstract: a method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tpa) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a sur1-trpm4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof. adverse outcomes associated with tpa include cerebral hemorrhage, cerebral edema, physical impairment or death. the administration of the sur1-trpm4 channel inhibitors occurs prior to the radiation therapy, during the radiation therapy, after the radiation therapy, or combinations thereof. the sur1-trpm4 channel inhibitor is administered prior to surgical excision of a brain tumor, car-t therapy, or administration of flutarabine. alternatively, or in addition, the sur1-trpm4 channel inhibitor is administered prior the onset of the cerebral edema-related side effects.

Inventor(s): Sven JACOBSON, Thomas MACALLISTER

CPC Classification: A61K31/64 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; soap compositions ))

Search for rejections for patent application number 20250161330